V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240014309 | 240012542 | 1.58 | null | Curative (C) | 2019-01-13 | 2019-01-13 | R CODOX M | 02 | N | 240035451 | PEMBROLIZUMAB |
| 240014310 | 240008496 | null | 50.3 | Not known (9) | null | 2017-10-20 | Etoposide oral | null | N | 240035459 | CISPLATIN + GEMCITABINE |
| 240014311 | 240015399 | 1.82 | 93.7 | Neo-adjuvant (N) | 2014-05-29 | 2014-05-30 | Bortezomib + MELPHALAN | 2 | N | 240035460 | IVAC |
| 240014312 | 240008501 | 1.68 | 50.2 | Curative (C) | 2015-04-30 | 2015-05-07 | Docetaxel 100mg/m2 (21 day) | N | N | 240035485 | ETOPOSIDE + IFOSFAMIDE |
| 240014313 | 240008503 | 1.65 | 63 | Curative (C) | 2015-12-31 | 2016-08-10 | AML17 TRIAL | N | N | 240035506 | DHAP - R |
| 240014314 | 240012547 | 1.65 | 82.5 | Curative (C) | 2015-07-03 | 2015-07-09 | Cytarabine High Dose | N | N | 240035507 | TRIPLE INTRATHECAL |
| 240014315 | 240012548 | 1.71 | null | Palliative (P) | 2017-08-28 | 2017-08-28 | CISPLATIN + FLUOROURACIL | N | N | 240035509 | RUXOLITINIB |
| 240014316 | 240015892 | 1.71 | 81 | Curative (C) | 2012-08-30 | 2013-06-23 | CARBOPLATIN + EPIRUBICIN + PACLITAXEL | N | N | 240035525 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 240014317 | 240008508 | 1.72 | null | null | 2014-01-14 | 2014-01-14 | GEMCITABINE + RITUXIMAB | N | N | 240035532 | VEDEX |
| 240014318 | 240008510 | 1.66 | 81.5 | Curative (C) | 2016-07-30 | 2016-07-30 | Docetaxel 100mg/m2 (21 day) | N | N | 240035538 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 240014319 | 240015401 | 1.73 | 82 | Disease modification (D) | 2017-11-02 | 2017-11-06 | CISPLATIN + GEMCITABINE | 2 | N | 240035550 | CYCLOPHOSPHAMIDE + FLUDARABINE + THIOTEPA |
| 240014320 | 240008512 | null | null | Disease modification (D) | 2015-08-29 | 2015-09-02 | Y-90 | N | N | 240035551 | CODOX M |
| 240014321 | 240012552 | null | 45.5 | Palliative (P) | 2014-08-18 | 2014-10-22 | Nilotinib | N | N | 240035553 | CISPLATIN + PACLITAXEL |
| 240014322 | 240008516 | 1.57 | null | Palliative (P) | 2014-02-09 | 2014-02-11 | Trifluridine + Tipiracil | N | N | 240035554 | RUXOLITINIB |
| 240014323 | 240008520 | 1.6 | 67 | Palliative (P) | 2015-04-18 | 2015-04-22 | CISPLATIN + FLUOROURACIL + RT | 02 | N | 240035582 | CYTARABINE + METHOTREXATE + RITUXIMAB |
| 240014324 | 240008522 | 1.8 | 65.9 | Curative (C) | 2014-03-29 | 2014-03-29 | IVE-R | 2 | N | 240035587 | TEMOZOLOMIDE |
| 240014325 | 240008524 | null | null | Palliative (P) | 2015-12-20 | 2016-08-11 | Gemcitabine + Oxaliplatin | 02 | N | 240035590 | CYTARABINE HD + METHOTREXATE HD |
| 240014326 | 240015404 | 1.78 | 74 | Curative (C) | null | 2017-10-31 | OFATUMUMAB | 02 | null | 240035608 | IMMUNOGLOBULIN |
| 240014327 | 240008529 | 1.52 | 84 | null | 2015-04-25 | 2015-05-03 | Cytarabine+Methotrexate Intrathecal | N | null | 240000098 | RUXOLITINIB |
| 240014328 | 240008530 | null | 74.3 | Palliative (P) | 2015-11-29 | 2015-11-30 | OFATUMUMAB | 02 | N | 240000290 | OFATUMUMAB |
| 240014329 | 240008532 | 1.54 | 58.2 | Curative (C) | 2017-01-13 | 2017-01-14 | CYCLOPHOSPHAMIDE + VINBLASTINE | 02 | null | 240000538 | ICE-R |
| 240014330 | 240008534 | 1.64 | 61.3 | Palliative (P) | 2016-04-02 | 2016-04-03 | CISPLATIN + FLUOROURACIL | 2 | N | 240000572 | PIXANTRONE |
| 240014331 | 240012562 | 1.57 | 92.6 | Palliative (P) | 2018-10-02 | 2018-10-02 | Cisplatin + Docetaxel | N | N | 240000791 | CISPLATIN + FLUOROURACIL |
| 240014332 | 240008540 | 1.85 | 80 | Curative (C) | 2017-12-02 | 2017-12-02 | Triple / Double Intrathecal Therapy | 2 | N | 240000855 | IDELALISIB + RITUXIMAB |
| 240014333 | 240014460 | 1.82 | 64.6 | Disease modification (D) | 2014-12-18 | 2014-12-20 | AML17 TRIAL | 02 | N | 240001110 | IDELALISIB + RITUXIMAB |
| 240014334 | 240008544 | 1.55 | 81.7 | Palliative (P) | 2017-03-25 | 2017-03-26 | Docetaxel 75mg/m2 (21 day) | 02 | N | 240001179 | CYTARABINE HIGH DOSE |
| 240014335 | 240014461 | 1.54 | 79.5 | Disease modification (D) | 2015-06-12 | 2016-04-15 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | N | N | 240001214 | TOPOTECAN |
| 240014336 | 240008546 | 0 | 60.2 | Palliative (P) | 2014-11-07 | 2014-11-20 | VINCRISTINE | N | N | 240001263 | CARBOPLATIN + RT |
| 240014337 | 240008547 | null | 70.5 | Palliative (P) | 2016-10-19 | 2016-10-27 | FCR IV - Cycle 2 onwards | 02 | null | 240001263 | ICE-R |
| 240014338 | 240008547 | 1.85 | 59.8 | Curative (C) | 2015-04-27 | 2015-04-27 | ICE (no GCSF) | 02 | N | 240001263 | R-EPOCH |
| 240014339 | 240008551 | 1.75 | 50.4 | Disease modification (D) | 2017-04-27 | 2017-05-11 | AML 18 TRIAL | N | null | 240001512 | R CODOX M |
| 240014340 | 240008552 | 1.65 | 64.95 | Curative (C) | 2015-09-25 | 2016-02-13 | PEMBROLIZUMAB | 02 | N | 240001512 | CARBOPLATIN + DOCETAXEL |
| 240014341 | 240008554 | 1.62 | 47.6 | Disease modification (D) | 2018-05-10 | 2018-05-30 | Triple / Double Intrathecal Therapy | N | N | 240001549 | IFOSFAMIDE |
| 240014344 | 240008560 | 1.8 | 77 | Curative (C) | 2015-03-28 | 2015-03-31 | R CODOX M | 02 | N | 240001973 | IVAC |
| 240014345 | 240012575 | 1.52 | 67 | Curative (C) | 2016-06-03 | 2016-06-06 | AML17 TRIAL | N | N | 240002013 | DHAP - R |
| 240014346 | 240012575 | 1.7 | null | Palliative (P) | 2017-03-29 | 2018-06-20 | DOXORUBICIN | N | N | 240002013 | ALEMTUZUMAB + FLUDARABINE + LEAM |
| 240014347 | 240016270 | 1.84 | 54.6 | Curative (C) | 2016-05-22 | 2016-06-03 | CARMUSTINE + THIOTEPA | 02 | N | 240002309 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 240014348 | 240008562 | 0 | 87.4 | Curative (C) | 2014-10-03 | 2016-03-24 | IELSG 32 TRIAL | N | null | 240002318 | BEAM R |
| 240014349 | 240012577 | 1.63 | 56.15 | Curative (C) | null | 2016-09-29 | Nilotinib | null | null | 240002416 | CVD |
| 240014350 | 240008568 | 1.76 | 63.7 | Palliative (P) | 2014-01-15 | 2014-01-24 | GEM-P | 02 | N | 240002469 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 240014351 | 240012579 | null | 48.8 | T | 2014-12-16 | 2015-01-18 | NHL 2003 Gp B CYM 1 & 2 | N | N | 240002486 | TRIPLE INTRATHECAL |
| 240014352 | 240012581 | 1.59 | 61.3 | Curative (C) | 2017-08-30 | 2017-09-03 | MABCUTE TRIAL | N | N | 240002486 | R-EPOCH |
| 240014353 | 240008573 | 1.68 | 65 | Adjuvant (A) | 2018-03-31 | 2018-04-12 | VAC | N | N | 240002690 | FLUDARABINE + MELPHALAN |
| 240014354 | 240008576 | null | 55.9 | Curative (C) | 2016-04-23 | 2016-04-23 | ACE (3 day) | 02 | N | 240002854 | TOPOTECAN |
| 240014355 | 240008579 | 1.75 | 87.4 | Curative (C) | 2014-10-07 | 2014-10-16 | IVE | 02 | N | 240002961 | CYTARABINE HD + METHOTREXATE HD |
| 240014357 | 240012585 | 1.79 | 100 | Curative (C) | 2016-10-14 | 2016-10-14 | IVE | N | N | 240003041 | R CODOX-M/ R IVAC |
| 240014358 | 240012586 | 1.78 | 55.4 | Palliative (P) | 2016-04-10 | 2016-04-14 | Triple / Double Intrathecal Therapy | 2 | N | 240003160 | IVE |
| 240014359 | 240008584 | null | 62.45 | Curative (C) | null | 2016-11-22 | CYCLO + RITUXIMAB + VINCRISTINE | null | null | 240003250 | CVP |
| 240014360 | 240012589 | 1.73 | 85 | Curative (C) | 2013-05-11 | 2013-09-02 | Oxaliplatin + Raltitrexed | 02 | N | 240003545 | MATRIX TRIAL |
| 240014361 | 240008587 | 1.64 | 78.7 | Disease modification (D) | 2016-10-07 | 2016-10-07 | ETOPOSIDE | N | N | 240003818 | VINCRISTINE |